p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy

Tang, Reiping; Wang, Jeng-Yi; Fan, Chung-Wei; Tsao, Kuo-Chien; Chen, Hong-Hua; Wu, Chi-Ming; Chen, Jinn-Shiun; Changchien, Chung Rong; Hsieh, Ling-Ling

doi:10.1016/j.canlet.2004.01.006

« Previous Next »Cancer Letters
Volume 210, Issue 1 , Pages 101-109, 8 July 2004

p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy

Reiping Tang
- Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
Jeng-Yi Wang
- Department of Colorectal Surgery, Chang Gung Memorial Hospital, Jar-Yi, Taiwan, ROC
Chung-Wei Fan
- Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
Kuo-Chien Tsao
- Department of Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
Hong-Hua Chen
- Department of Colorectal Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC
Chi-Ming Wu
- Graduate Institute of Basic Medical Science, Chang Gung University, Tao-Yuan, Taiwan, ROC
Jinn-Shiun Chen
- Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
Chung Rong Changchien
- Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
Ling-Ling Hsieh
- Department of Public Health, Chang Gung University, 259 Wen-Hwa 1 Road, Kwei-San, Tao-Yuan 333, Taiwan, ROC
- Corresponding author. Tel.: +886-3-211-8800x5125; fax: +886-3-211-8700

Received 8 August 2003; received in revised form 10 January 2004; accepted 15 January 2004.

Abstract

One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K-ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT). When stratified by PAT and adjusting for other prognostic variables, presence of p53 mutation was associated with a poor outcome (hazard ratio (HR)=3.1, 95% confidence interval (CI), 0.9–11.0) among patients without PAT. Our data confirmed that p53 mutation is an independent pre-treatment factor in stage II and III colorectal cancer after curative resection.

Keywords: Colorectal cancer, p53 mutation, Post-operative adjuvant therapy, K-ras mutation